How should preeclampsia be managed regarding blood pressure control, magnesium sulfate seizure prophylaxis, and timing of delivery?

Management of Preeclampsia

Preeclampsia requires a three-pronged approach: initiate antihypertensive therapy for blood pressures ≥140/90 mm Hg targeting a diastolic BP of 85 mm Hg, administer magnesium sulfate for seizure prophylaxis in women with severe features, and deliver at 37 weeks or earlier if severe features develop.

Blood Pressure Control

Treatment Thresholds and Targets

The International Society for the Study of Hypertension in Pregnancy (ISSHP) recommends treating any persistent BP ≥140/90 mm Hg in preeclampsia, which differs from ACOG's higher threshold of ≥160/110 mm Hg for acute treatment 1. The ISSHP approach is more evidence-based, as it reduces the likelihood of progression to severe hypertension and associated complications 1.

• Target diastolic BP: 85 mm Hg (systolic BP 110-140 mm Hg or at minimum <160 mm Hg) 1
• Reduce or cease antihypertensives if diastolic BP falls <80 mm Hg 1

Severe Hypertension (≥160/110 mm Hg)

Urgent treatment is required in a monitored setting 1:

First-line agents:

• Oral nifedipine
• IV labetalol
• IV hydralazine
• Oral labetalol (if above unavailable) 1

Maintenance Antihypertensive Therapy

Acceptable first-line agents 1:

• Oral methyldopa
• Labetalol
• Oxprenolol
• Nifedipine

Second/third-line agents:

• Hydralazine
• Prazosin

Common pitfall: The 2025 Circulation guidelines note that ACOG and ISSHP differ on treatment thresholds—ISSHP's lower threshold (≥140/90 mm Hg) is logically more consistent and prevents the development of severe hypertension 2, 1.

Magnesium Sulfate for Seizure Prophylaxis

Indications

Magnesium sulfate should be administered to women with preeclampsia who have 1:

• Proteinuria AND severe hypertension (≥160/110 mm Hg), OR
• Hypertension with neurological signs/symptoms (headache, visual disturbances, clonus)

In low-resource settings, all women with preeclampsia should receive magnesium sulfate due to favorable cost-benefit ratio 1. In high-resource settings, selective use based on severe features is reasonable 1.

Dosing Regimen

Per FDA labeling and MAGPIE trial protocols 3:

Loading dose:

• 4-5 g IV in 250 mL of 5% dextrose or 0.9% saline, infused over 3-4 minutes, OR
• 10-14 g total initial dose: 4-5 g IV plus up to 10 g IM (5 g in each buttock) simultaneously

Maintenance dose:

• 4-5 g IM into alternate buttocks every 4 hours, OR
• 1-2 g/hour continuous IV infusion 3

Duration:

• Continue until delivery and for 24 hours postpartum 1
• Some evidence suggests stopping after 8 g predelivery may be sufficient, but 24-hour postpartum continuation remains standard 1

Monitoring and Safety

Before each dose, verify 3:

• Patellar reflex present (reflexes absent at ~10 mEq/L magnesium)
• Respiratory rate ≥16 breaths/minute
• Urine output ≥100 mL in preceding 4 hours

Therapeutic serum magnesium level: 2.5-5 mEq/L (3-6 mg/100 mL) 3

Critical warning: Do not use magnesium sulfate continuously beyond 5-7 days as it causes fetal skeletal abnormalities 3.

Timing of Delivery

Preeclampsia Without Severe Features

• ≥37 weeks: Deliver 1
• <37 weeks: Expectant management with close observation 2, 1

Preeclampsia With Severe Features

Deliver immediately if 1:

• ≥34 weeks gestation 2
• Repeated severe hypertension despite 3 antihypertensive classes
• Progressive thrombocytopenia
• Progressively abnormal liver or renal function tests
• Pulmonary edema
• Severe intractable headache, visual scotomata, or seizures
• Non-reassuring fetal status

Between 34-37 weeks: Expectant conservative management may be considered in stable cases 1

<34 weeks: Conservative management at a tertiary center with maternal-fetal medicine expertise, but deliver for any severe feature listed above 1

Maternal Monitoring

Initial assessment: All women should be assessed in hospital at diagnosis 1

Ongoing monitoring 1:

• BP monitoring (frequency based on severity)
• Repeated proteinuria assessment if not already present
• Clinical assessment including clonus
• Blood tests minimum twice weekly: hemoglobin, platelets, liver transaminases, creatinine, uric acid
• Increase frequency with any clinical status change

Fetal Monitoring

• Initial assessment to confirm fetal well-being 1
• Serial ultrasound: fetal biometry, amniotic fluid, umbilical artery Doppler
• If normal: repeat every 2 weeks 1
• If fetal growth restriction: more frequent monitoring 1

Intrapartum Management

• Continue oral antihypertensives at labor onset 1
• Fluid restriction: 60-80 mL/hour to avoid pulmonary edema (preeclamptic women have capillary leak) 1
• Treat severe hypertension urgently as above
• Continue magnesium sulfate if already initiated

Postpartum Management

BP monitoring: At least every 4-6 hours for minimum 3 days postpartum 1

Continue magnesium sulfate for 24 hours postpartum (eclampsia can occur postpartum) 1

Antihypertensive management:

• Restart/continue antihypertensives after delivery
• Taper slowly only after days 3-6 postpartum unless BP <110/70 mm Hg 1
• Treat postpartum BP ≥150/100 mm Hg; many also treat ≥140/90 mm Hg targeting <130/80 mm Hg 2

Laboratory monitoring: Repeat hemoglobin, platelets, liver enzymes, creatinine day after delivery and every other day until stable 1

Avoid NSAIDs in preeclampsia, especially with renal involvement—use alternative analgesia 1

Follow-up: Review within 1 week if on antihypertensives; all women at 3 months postpartum to ensure normalization of BP, urinalysis, and labs 1

Critical pitfall: Preeclampsia can develop de novo postpartum or worsen after delivery—maintain vigilance for 72 hours minimum 2, 4.